2020
Human Leukocyte Antigen Class I Antibodies and Response to Platelet Transfusion in Patients Undergoing Liver Transplantation
Wong M, Narra R, Selim M, Zimmerman M, Kim J, Padmanabhan A, Hong J. Human Leukocyte Antigen Class I Antibodies and Response to Platelet Transfusion in Patients Undergoing Liver Transplantation. Journal Of Surgical Research 2020, 255: 99-105. PMID: 32543385, DOI: 10.1016/j.jss.2020.05.029.Peer-Reviewed Original ResearchConceptsPlatelet transfusion refractorinessUnsensitized patientsPlatelet transfusionsSimultaneous liver-kidney transplantationLiver-kidney transplantationLiver transplantationSensitized patientsLT patientsHLA-IHuman leukocyte antigen class I antibodiesHuman leukocyte antigen class IHLA-matched platelet transfusionsAlloimmunization to PlateletsClass I antibodiesPanel-reactive antibodyRisk of hemorrhageHistory of pregnancyPatient survival ratesEarly allograft rejectionRate of refractorinessShort-term outcomesMultivariate logistic regressionPlatelet alloimmunizationAllograft rejectionClinical characteristics
2017
Sex-based outcomes of lower extremity bypass surgery in hemodialysis patients
Arhuidese I, Kernodle A, Nejim B, Locham S, Hicks C, Malas M. Sex-based outcomes of lower extremity bypass surgery in hemodialysis patients. Journal Of Vascular Surgery 2017, 68: 153-160. PMID: 29276108, DOI: 10.1016/j.jvs.2017.10.063.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmputation, SurgicalBlood Vessel ProsthesisBlood Vessel Prosthesis ImplantationChi-Square DistributionClinical Decision-MakingDatabases, FactualDisease-Free SurvivalFemaleGraft Occlusion, VascularHumansKaplan-Meier EstimateKidney DiseasesLimb SalvageLogistic ModelsLower ExtremityMaleMiddle AgedMultivariate AnalysisOdds RatioPeripheral Arterial DiseaseProportional Hazards ModelsProsthesis DesignRenal DialysisRetrospective StudiesRisk FactorsSex FactorsTime FactorsTreatment OutcomeVascular PatencyVeinsConceptsAcute graft failureAutogenous conduitGraft failureProsthetic conduitBypass surgeryHemodialysis patientsAssociated with higher patencyLimb salvagePrimary assisted patencySex-based outcomesInfrainguinal bypass surgeryLower extremity bypass surgeryCox regression analysisPatient survival ratesRisk-adjusted analysisUnited States Renal Data SystemCritical limb ischemiaAssisted patencySecondary patencyConduit usePrimary patencySurgical outcomesNo significant differenceKaplan-MeierComparing Patients
2012
P-109 Intestinal Transplantation for End Stage Crohn's Disease: Therapeutic Efficacy and Disease Recurrence
Koritsky D, Costa G, Bond G, Schuster B, Roberts M, Hoffman B, Stein W, Soltys K, Sogawa H, Rubin E, Regueiro M, Abu-Elmagd K. P-109 Intestinal Transplantation for End Stage Crohn's Disease: Therapeutic Efficacy and Disease Recurrence. Inflammatory Bowel Diseases 2012, 18: s58-s58. DOI: 10.1097/00054725-201212001-00142.Peer-Reviewed Original ResearchIrreversible intestinal failureDisease recurrenceCrohn's diseaseRecipient pretreatmentSurvival rateChronic rejectionGraft lossIntestinal failureMultivisceral transplantationTPN therapyGraft functionSurvival outcomesIntestinal transplantationTherapeutic efficacyActuarial patient survival ratesRisk of graft lossLongterm survival outcomesPositive lymphocytotoxic crossmatchDisease patientsConsecutive adult patientsYear survival rateTime of transplantationNon-Crohn's disease patientsPatient survival ratesLong-term outcomesO-4 Intestinal Transplantation for End Stage Crohn's Disease: Therapeutic Efficacy and Disease Recurrence
Koritsky D, Costa G, Bond G, Schuster B, Roberts M, Hoffman B, Stein W, Soltys K, Sogawa H, Rubin E, Regueiro M, Abu-Elmagd K. O-4 Intestinal Transplantation for End Stage Crohn's Disease: Therapeutic Efficacy and Disease Recurrence. Inflammatory Bowel Diseases 2012, 18: s3-s3. DOI: 10.1097/00054725-201212001-00005.Peer-Reviewed Original ResearchIrreversible intestinal failureDisease recurrenceCrohn's diseaseRecipient pretreatmentSurvival rateChronic rejectionGraft lossIntestinal failureMultivisceral transplantationTPN therapySurvival outcomesGraft functionIntestinal transplantationTherapeutic efficacyActuarial patient survival ratesLong-term survival outcomesRisk of graft lossPositive lymphocytotoxic crossmatchDisease patientsConsecutive adult patientsYear survival rateTime of transplantationNon-Crohn's disease patientsPatient survival ratesLong-term outcomes
2004
Renal transplant recipients over aged 60 have diminished immune activity and a low risk of rejection
Friedman AL, Goker O, Kalish MA, Basadonna GP, Kliger AS, Bia MJ, Lorber MI. Renal transplant recipients over aged 60 have diminished immune activity and a low risk of rejection. International Urology And Nephrology 2004, 36: 451-456. PMID: 15783123, DOI: 10.1007/s11255-004-8685-2.Peer-Reviewed Original ResearchConceptsRenal transplant recipientsTransplant recipientsOlder patientsYounger patientsChronologic ageActual patient survival ratesOlder renal transplant recipientsPrimary kidney transplantsYear graft survivalPatient survival ratesOrgan Transplant CenterAcute rejectionCadaveric recipientsEquivalent immunosuppressionGraft survivalImmunosuppression strategiesImmunosuppressive protocolsConsecutive recipientsKidney transplantDonor kidneysTransplant centersGeriatric patientsYounger recipientsOutcome analysisStudy groupClinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors
Tran HT, Blumenschein GR, Lu C, Meyers CA, Papadimitrakopoulou V, Fossella FV, Zinner R, Madden T, Smythe LG, Puduvalli VK, Munden R, Truong M, Herbst RS. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemotherapy And Pharmacology 2004, 54: 308-314. PMID: 15184994, DOI: 10.1007/s00280-004-0816-z.Peer-Reviewed Original ResearchConceptsPharmacokinetics of carboplatinTNP-470Solid tumorsDoublet regimenAngiogenesis inhibitor TNP-470Hematological toxic effectsRegimen of paclitaxelCycles of therapyMedian survival durationCombination of paclitaxelPatient survival ratesRecent clinical trialsHead/neckCell lung carcinomaTNP-470 administrationToxic effectsAUC 5AUC 6Chemotherapy doubletsIntravenous paclitaxelPurposePreclinical studiesStable diseasePartial responseRandomized studySurvival duration
2002
IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
Herbst RS, Hong WK. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Seminars In Oncology 2002, 29: 18-30. PMID: 12422310, DOI: 10.1053/sonc.2002.35644.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaEpidermal growth factor receptorIMC-C225Cell carcinomaAnti-epidermal growth factor receptor monoclonal antibodyLow patient survival rateRefractory squamous cell carcinomaLocoregional disease recurrencePromising response ratesImportant adverse eventsPatient survival ratesPhase I studiesReceptor monoclonal antibodyTreatment of headHuman tumor xenograftsExtracellular receptor sitesEnhanced tumor invasivenessInhibition of metastasisInhibition of angiogenesisAnticancer treatment strategiesGrowth factor receptorIMC-225Cancer cell linesAdverse eventsPotent antitumor activityIMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer
Herbst R, Hong W. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Seminars In Oncology 2002, 29: 18-30. DOI: 10.1016/s0093-7754(02)70087-0.Peer-Reviewed Original ResearchSquamous cell carcinomaEpidermal growth factor receptorIMC-C225Cell carcinomaAnti-epidermal growth factor receptor monoclonal antibodyLow patient survival rateRefractory squamous cell carcinomaLocoregional disease recurrencePromising response ratesImportant adverse eventsPatient survival ratesPhase I studiesReceptor monoclonal antibodyTreatment of headHuman tumor xenograftsExtracellular receptor sitesEnhanced tumor invasivenessInhibition of metastasisInhibition of angiogenesisAnticancer treatment strategiesGrowth factor receptorIMC-225Cancer cell linesAdverse eventsPotent antitumor activity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply